We are live on ! Find out more
EBAC

European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC

Delisted

EBAC was delisted on the 2nd of March, 2023.

Back to rankings

50 hedge funds and large institutions have $94M invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $86.6M → $94M (+$7.44M)

0% more funds holding

Funds holding: 50 → 50 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

Holders
50
Holders Change
–
Holders Change %
0%
% of All Funds
0.8%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
5
Increased
5
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
+$2.59M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.5M
3
MTCM
Mint Tower Capital Management
Netherlands
+$999K
4
WP
Woodline Partners
California
+$999K
5
RCM
Radcliffe Capital Management
Pennsylvania
+$952K

Top Sellers

Rank Fund Capital Flow
1
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$3.69M
2
Calamos Advisors
Calamos Advisors
Illinois
-$992K
3
GCM
Ghisallo Capital Management
Massachusetts
-$959K
4
PC
Periscope Capital
Ontario, Canada
-$664K
5
GF
Gabelli Funds
New York
-$111K
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
26
Dupont Capital Management
Delaware
$1.01M – – –
CCM
27
CAAS Capital Management
New York
$977K – – –
GCIA
28
Gabelli & Co Investment Advisers
New York
$663K – – –
GF
29
Gabelli Funds
New York
$629K -$111K -11,065 -15%
GAM
30
Gritstone Asset Management
Maryland
$565K +$559K +55,952 New
CSS
31
Cubist Systematic Strategies
Connecticut
$524K -$86.3K -8,632 -14%
WA
32
Whitebox Advisors
Minnesota
$510K – – –
PAMP
33
Polar Asset Management Partners
Ontario, Canada
$470K – – –
TCA
34
Taconic Capital Advisors
New York
$470K – – –
AGC
35
Angelo Gordon & Co
New York
$404K – – –
ACM
36
Atalaya Capital Management
New York
$404K – – –
ETH
37
Exos TFP Holdings
New York
$363K -$740 -74 -0.2%
VI
38
Vestcor Inc
New Brunswick, Canada
$354K – – –
OAC
39
OMERS Administration Corp
Ontario, Canada
$353K – – –
CCA
40
Castle Creek Arbitrage
Colorado
$324K +$320K +32,043 New
GCM
41
Ghisallo Capital Management
Massachusetts
$292K -$959K -95,907 -77%
VF
42
Virtu Financial
New York
$199K +$197K +19,678 New
WRBC
43
W.R. Berkley Corp
Connecticut
$198K – – –
DIG
44
DeepCurrents Investment Group
New York
$179K – – –
SCM
45
Saba Capital Management
New York
$175K – – –
SSA
46
Schonfeld Strategic Advisors
New York
$144K – – –
LCM
47
Landscape Capital Management
New Jersey
$111K – – –
ACA
48
Arena Capital Advisors
California
$57.7K – – –
UBS Group
49
UBS Group
Switzerland
$15.5K – – –
EC
50
Elequin Capital
New York
$3.03K – – –
1
2
3

EBAC Hedge Fund Activity: Q4 2022 in Review

50 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q4 2022, worth a combined $94M — up 8.6% from $86.6M a quarter earlier.

Fund positioning in EBAC was balanced in Q4 2022: 5 funds opened new positions, 5 closed out, 5 added to existing stakes and 6 trimmed.

The largest buyer was Glazer Capital LLC, adding an estimated $2.59M. The largest seller was BNP Paribas Financial Markets, exiting entirely with an estimated $3.69M sold.

  • 50 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $94M of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q4 2022, up 8.6% quarter-over-quarter.
  • 5 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q4 2022 and 5 closed out, a net change of 0 holders.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares buyer in Q4 2022 was Glazer Capital LLC, an estimated $2.59M added.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q4 2022 was BNP Paribas Financial Markets, an estimated $3.69M sold.

Based on aggregated 13F filings for Q4 2022.